Physical Activity Coaching For Adults With Physical Disabilities: A Pragmatic Randomised Controlled Trial.
Funder
National Health and Medical Research Council
Funding Amount
$1,371,185.00
Summary
People with impaired mobility can achieve substantial benefits from appropriate physical activities but face many barriers to being active so require targeted interventions and health professional support. This trial (n=600) will test the effectiveness and cost-effectiveness of an enhanced physical activity coaching intervention (home-visit from a physiotherapist, phone coaching, technology) with phone coaching alone and with no intervention.
Can Pentoxifylline Improve Long-term Outcomes In Preterm Infants With Late-onset Sepsis Or Necrotizing Enterocolitis – A Pragmatic, Randomized, Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,901,130.00
Summary
Very preterm infants are at high risk of death and disability. Brain injury is often the result of inflammation caused by infection or bowel disease. To date, there is no treatment to reduce the harmful effects of inflammation. Pentoxifylline reduces inflammation and is a promising, safe and inexpensive treatment option for preterm infants. This study will determine whether Pentoxifylline in addition to antibiotics improves survival without disability in preterm infants.
Reaching The Tenth Decade Of Life In Australia – A 20-year Longitudinal Study Of Older Men
Funder
National Health and Medical Research Council
Funding Amount
$890,063.00
Summary
There are increasing numbers of older people in Australia. A boy born in Australia in 2015 may expect to live to 92 years but how we will ensure that the health of these older men is maintained, and that ageing is a positive experience, is not yet known. We will study a large group of men initially aged over 65 years of age, and who have already been followed for 20 years, to work out how Australian men can reach the tenth decade of life, and how they can achieve this milestone successfully. .
ASPREE is the largest clinical trial ever conducted in Australia and will determine whether daily low dose aspirin prevents disease in healthy older people. The study was well-funded initially but will require additional support to complete the vital final stage of data collection and analysis. This will enable the study to answer important questions about the benefits and risks of aspirin in this age group and its effect on disability free survival.
An Australasian, Multi-centre, Randomized, Double-blind, Placebo-controlled Trial Of The Efficacy Of Fluoxetine In Improving Functional Recovery After Acute Stroke
Funder
National Health and Medical Research Council
Funding Amount
$2,306,367.00
Summary
Stroke is one of the top three causes of disability. Treatments that improve recovery after stroke are lacking. We reviewed the world literature and found a number of very small studies which, together, suggest that the antidepressant drug, fluoxetine, may improve the recovery in stroke patients. AFFINITY is a large trial in 1600 Australians and New Zealanders with stroke which aims to find out whether taking fluoxetine for 6 months after a stroke improves recovery compared to a placebo.
Does Placental Transfusion Prevent Death And Disability In Very Preterm Infants? Childhood Follow Up In The NHMRC Australian Placental Transfusion Study.
Funder
National Health and Medical Research Council
Funding Amount
$889,406.00
Summary
A million babies are born before 30 weeks gestation worldwide each year. Many die or face a lifetime of disability. Enhancing placental transfusion in these infants by deferred clamping of the umbilical cord (DCC) is a simple procedure that may reduce mortality and major disability in childhood. The Australian Placental Transfusion Study (APTS), the largest ever RCT of deferred clamping, will follow up 1200 children born preterm to evaluate if DCC has childhood benefits at 2 years age.
We are an international team committed to clinical trials to improve survival without disability in newborn babies. We plan a randomised trial to confirm if bovine lactoferrin, an inexpensive dairy protein, reduces death or major morbidity and increases total breast milk intake in 1,500 very low birthweight babies in neonatal intensive care units
Large-scale Data To Understand Person-centred Outcomes In Cancer Survivors
Funder
National Health and Medical Research Council
Funding Amount
$1,163,471.00
Summary
Although the majority of people with cancer in Australia now survive long-term, little is known about long-term “person-centred outcomes” for cancer survivors - including mental health, disability, pain and quality of life. This project will use data from >70,000 cancer survivors and >190,000 people without cancer from the general population to generate new knowledge on person-centred outcomes, for different cancer types and over time, to inform and improve health and healthcare.
What Predicts The Progressive Phase Of Multiple Sclerosis
Funder
National Health and Medical Research Council
Funding Amount
$1,791,343.00
Summary
We have made major gains in our understanding of what causes MS. What has proven to be far more difficult is understanding the drivers of disability progression and conversion to progressive MS. The onset of progression heralds the accumulation of irreversible disability and is a critical time point to a person with MS. This grant aims to determine the lifestyle, environmental, genetic and epigenetic drivers of MS progression, using an internationally unique Australian MS longitudinal cohort.
Improving The Phenotypic Severity Of Intellectual Disability And Seizures Caused By Expanded Polyalanine Tract Mutations In The ARX Homeobox Transcription Factor.
Funder
National Health and Medical Research Council
Funding Amount
$683,622.00
Summary
Intellectual disability is frequent in the population, with as many as 1 in every 50 people in the world directly affected. ARX is a gene mutated in X chromosome-linked intellectual disability and seizures. Our study will comprehensively address the basis for improvements to disease outcomes following treatment with steriod horomones in mice modelling these mutations. We will also address the mechanism contributing to disturbed protein function due to these expanded polyalanine tract mutations.